JPRN-UMIN000002651招募中2 期
A Phase II Trial of Lapatinib and Trastuzumab in Patients with Heavily Pretreated Metastatic Breast Cancer - A Phase II Trial of Lapatinib and Trastuzumab in Patients with Heavily Pretreated Metastatic Breast Cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •a) Lapatinib pretreated b) Ejectoon fraction <50%
研究者
相似试验
已完成
不适用
Phase I/II study with lapatinib plus trametinib in patients with metastatic KRAS mutant non-small cell lung cancer10038666non-small cell lung cancerNL-OMON46994Antoni van Leeuwenhoek Ziekenhuis132
进行中（未招募）
1 期
Phase I/II study with lapatinib plus trametinib in patients with metastaticnon-small cell lung cancer with a mutation in the KRAS genenon-small cell lung cancerEUCTR2014-002209-39-NLThe Netherlands Cancer Institute132
已完成
2 期
A phase II trial of pertuzumab and trastuzumab in combination with capecitabine in patients with metastatic breast cancer who received prior trastuzumab combination chemotherapy.Breast cancerJPRN-UMIN000012208Kurume University Hospital24
已完成
2 期
Phase II study of trastuzumab and paclitaxel in patients with HER2 positive (IHC 3+, IHC 2+ and FISH +) previously treated advanced or recurrent gastric cancerHER2 positive advanced or recurrent gastric cancerJPRN-UMIN000006223Japanese Foundation for Multidisciplinary Treatment of Cancer35
已完成
2 期
Randomized phase II study comparing trastuzumab plus weekly paclitaxel with weekly paclitaxel alone for patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum.gastric or gastro-esophageal junction adenocarcinomaJPRN-UMIN000009297West Japan Oncology Group90